Multiple sclerosis is an autoimmune disease that commonly affects young adults. If initially characterized by acute relapses, it is later followed by only incomplete remission. Over years, progressive disability and irreversible deficit lead to chronic neurological deficits in the majority of patients. The clinical course is protracted and unpredictable, and no biological marker is useful in predicting the evolution of autoaggression and disability. It is difficult to diagnose and to monitor disease progression after the initial symptoms or even during the major clinical manifestations, and it is difficult to treat. In this review, the authors report recent advances in the field, focusing on the search of new antigens as a marker of the disease, in their relevance to the pathophysiology and diagnosis of the disease.

Toward biomarkers in multiple sclerosis: new advances / F. Lolli; P. Rovero; M. Chelli; A.M. Papini. - In: EXPERT REVIEW OF NEUROTHERAPEUTICS. - ISSN 1473-7175. - STAMPA. - 6:(2006), pp. 781-794. [10.1586/14737175.6.5.781]

Toward biomarkers in multiple sclerosis: new advances.

LOLLI, FRANCESCO;ROVERO, PAOLO;PAPINI, ANNA MARIA
2006

Abstract

Multiple sclerosis is an autoimmune disease that commonly affects young adults. If initially characterized by acute relapses, it is later followed by only incomplete remission. Over years, progressive disability and irreversible deficit lead to chronic neurological deficits in the majority of patients. The clinical course is protracted and unpredictable, and no biological marker is useful in predicting the evolution of autoaggression and disability. It is difficult to diagnose and to monitor disease progression after the initial symptoms or even during the major clinical manifestations, and it is difficult to treat. In this review, the authors report recent advances in the field, focusing on the search of new antigens as a marker of the disease, in their relevance to the pathophysiology and diagnosis of the disease.
2006
6
781
794
F. Lolli; P. Rovero; M. Chelli; A.M. Papini
File in questo prodotto:
File Dimensione Formato  
ExpertRevNeurotherapeutics_2006_6(5)_781-794.pdf

Accesso chiuso

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Tutti i diritti riservati
Dimensione 452.18 kB
Formato Adobe PDF
452.18 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/328399
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 11
social impact